Absence in CX3CR1 receptor signaling promotes post‐ischemic stroke cognitive function recovery through suppressed microglial pyroptosis in mice
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.14551 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Yangyang Ge und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Ischemic Stroke, Stroke. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Post‐stroke cognitive impairment (PSCI) is a major source of morbidity and mortality after stroke, but the pathological mechanisms remain unclear. Previous studies have demonstrated that the CX3CR1 receptor plays a crucial role in maintaining an early protective microenvironment after stroke, but whether it persistently influences cognitive dysfunction in the chronic phase requires further investigation.
Methods
Mouse was used to establish a middle cerebral artery occlusion (MCAO)/reperfusion model to study PSCI. Cognitive function was assessed by the Morris water maze (MWM) and the novel object recognition test. Neurogenesis was assessed by immunofluorescence staining with Nestin + /Ki67 + and DCX + /BrdU + double‐positive cells. The cerebral damage was monitored by [ 18 F]‐DPA‐714 positron emission tomography, Nissel, and TTC staining. The pyroptosis was histologically, biochemically, and electron microscopically examined.
Results
Upon MCAO, at 28 to 35 days, CX3CR1 knockout (CX3CR1 −/− ) mice had better cognitive behavioral performance both in MWM and novel object recognition test than their CX3CR1 +/− counterparts. Upon MCAO, at 7 days, CX3CR1 −/− mice increased the numbers of Nestin + /Ki67 + and DCX + /BrdU + cells, and meanwhile it decreased the protein expression of GSDMD, NLRP3 inflammasome subunit, caspase‐1, mature IL‐1β/IL‐18, and p‐P65 in the hippocampus as compared with CX3CR1 +/− mice. In addition, CX3CR1 −/− mice could reverse infarct volume in the hippocampus region post‐stroke.
Conclusion
Our study demonstrated that CX3CR1 gene deletion was beneficial to PSCI recovery. The mechanism might lie in inhibited pyroptosis and enhanced neurogenesis. CX3CR1 receptor may serve as a therapeutic target for improving the PSCI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Yun Lin
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ge, Y., Yang, J., Chen, J., Dai, M., Dou, X., Yao, S., Yao, C., & Lin, Y. (2024). Absence in CX3CR1 receptor signaling promotes post‐ischemic stroke cognitive function recovery through suppressed microglial pyroptosis in mice. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14551
Vancouver
Ge Y, Yang J, Chen J, Dai M, Dou X, Yao S, et al. Absence in CX3CR1 receptor signaling promotes post‐ischemic stroke cognitive function recovery through suppressed microglial pyroptosis in mice. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14551
BibTeX
@article{Ge2024,
author = {Ge, Yangyang and Yang, Juexi and Chen, Jiayi and Dai, Maosha and Dou, Xiaoke and Yao, Shanglong and Yao, Chenye and Lin, Yun},
title = {Absence in CX3CR1 receptor signaling promotes post‐ischemic stroke cognitive function recovery through suppressed microglial pyroptosis in mice},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.14551}
}
EUVIMED